spacer
The Healthcare Sales & Marketing Network celebrates 25 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Healthcare Industry News:  Surgical Hemostat 

Devices Surgery

 News Release - January 22, 2007

Surgeons to Witness Sea Change in Surgical Hemostasis at Annual STS Meeting

MINNEAPOLIS, Jan. 22 (HSMN NewsFeed) -- This year's Society of Thoracic Surgeons Annual Meeting will see and experience a new generation surgical hemostasis device that could greatly reduce the time and expense, while improving the safety and efficacy of hemorrhagic control during thoracic and cardiothoracic surgery.

Medafor, Inc., will introduce its Arista(TM)AH absorbable hemostasis powder at this year's event to be held at the San Diego Convention Center January 28 - 30. Medafor received FDA PMA for this simple, safe and highly effective hemostat in September 2006, and Arista(TM)AH has compiled a remarkable record of success in more than 100,000 surgeries worldwide, raising expectations for its entrance to U.S. medical markets.

Currently, Arista(TM)AH is indicated for most surgeries including cardiac, thoracic, orthopedic, spinal and general applications. Arista(TM)AH is the only new generation Surgical Hemostat that is instantly ready to use, requiring no mixing, no addition of patient blood or other components and no special handling or storage conditions.

Based on Medafor's patented Microporous Polysaccharide Hemospheres (MPH®) technology, Arista(TM)AH is a plant-derived, flowable powder engineered to rapidly dehydrate blood, enhancing clotting on contact. Arista(TM)AH facilitates the formation of a highly resilient, natural clot within just a few minutes, regardless of the patient's coagulation status.

Pre-clinical evaluations, clinical studies and surgical use have shown the hemostatic capabilities of Arista(TM)AH to be comparable to the current popular choice of surgical hemostasis materials, yet its unique formulation provides simpler, faster application and its rapid absorption -- within 24 to 48 hours -- leads to little risk of associated complications or infection.

According to Gary Shope, C.E.O. of Medafor, Inc., "Arista AH represents a paradigm shift in surgical options for hemostasis. Surgeons choose Arista AH knowing that its quality and efficacy are consistent, that its unique formulation eliminates risks associated with animal and human-derived products, and that it is always ready to apply the instant they need it."

For information, visit Booth #228 at STS, http://www.medafor.com , or call 1-877-MEDAFOR.

Medafor, Inc., was founded in 1999 to develop and market its patented new generation hemostasis method, improving the quality of options for surgeons, emergency services and others in need of rapid, safe, effective bleeding control. Medafor, Inc., is a privately held Minnesota Corporation located in Minneapolis.

Medafor®, MPH® and Arista(TM)AH are trademarks of Medafor, Inc. Arista(TM)AH is manufactured under U.S. Patent No. 6,060,461. Other patents pending.

Source: Medafor

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.

Search: Medafor 
Search: Arista AH 
Search: hemostasis powder 
Search: hemostasis device 
Healthcare Industry NewsFeed  


FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.